Australia markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
39.29-0.81 (-2.02%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close40.10
Open40.02
Bid0.00 x 800
Ask0.00 x 800
Day's range38.90 - 40.98
52-week range19.38 - 87.24
Volume612,099
Avg. volume1,460,273
Market cap1.481B
Beta (5Y monthly)2.23
PE ratio (TTM)N/A
EPS (TTM)-3.04
Earnings date08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est86.21
  • GlobeNewswire

    Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

    Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2021 on Monday, November 8, 2021 before the opening of the U.S. financial markets. Axsome’s management team will host a

  • GlobeNewswire

    Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

    $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility to $300 million, and the amount immediately available upon U.S. Food

  • Motley Fool

    3 Biotech Stocks That Could Rise 90% or More, According to Wall Street

    Are you looking for biotech stocks that could shoot higher? Wall Street analysts who cover the stocks on this list think they could provide some eye-popping gains. Every stock on this list has a consensus price target that's 91% above its present price.